Progress in the treatment paradigms for locally advanced cervical cancer.

Competing Interests: LRD reports research funding to her institution for investigator-initiated trials from Merck, clinical trial grants (to institution) from Genentech/Roche, AbbVie/(GOG 3005), Acrivon, Advaxis, Aduro BioTech, Alkermes, Blueprint, Constellation, Eisai, GlaxoSmithKlein/Novartis, Immunogen, Inovio, Iovance, Karyopharm, KSQ Therapeutics, Lycera, Merck, Morab, MorphoTek, Naveris, Nurix, OncoQuest, Pfizer, Syndax, Tesaro, and Zentalis; royalties from UpToDate, Wiley, and ASCO; continuing medical education payments from Advance Medical, CEA Group, and Clinical Care Options; fees for Innovio Data and Safety Monitoring Board (DSMB), Aegenus DSMB, and Merck advisory board (to her institution); personal advisory board fees from Daiichi Sankyo; and that she was until March, 2024, Secretary Treasurer for SGO (unpaid). LMR reports grant funding to her institution from Merck, Zentalis, Karyopharm, GOG Foundation, Regeneron, ImmunoGen, Acrivon, CanariaBio, CorceptTherapeutics, and Seagen; consulting fees from AstraZeneca, Merck, GSK, Genmab, Seagen, GOG Foundation, Zentalis, ImmunoGen, Stemline, Eisai, Caris, Nykode, and Clovis; speakers fees from Seagen and Genmab; and that she is a consultant for the GOG Foundation. LRD and LMR are both coauthors of the KEYNOTE-A18 trial.